Epidermal growth factor receptor determination on tumour imprints.
J Clin Pathol
; 46(2): 166-8, 1993 Feb.
Article
in En
| MEDLINE
| ID: mdl-7681452
ABSTRACT
Epidermal growth factor receptor (EGFR) is a sensitive prognostic indicator in women with breast cancer. A new technique for the detection of EGFR on breast cancer imprints is described and evaluated in relation to immunohistochemistry on frozen sections. The standard streptavidin-biotin method using the R1 antibody on frozen sections was modified for use on tumour imprints. In the first group (group 1 imprints) 43 tumours were assessed by frozen section and imprint staining. The group 1 imprint method had a sensitivity of 50% and a specificity of 89% compared with the frozen sections. Further modifications were made for the following 32 tumours (group 2) and this method had a much improved sensitivity of 94% while specificity was preserved. This method is simple and could be performed in any hospital histopathology department.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
ErbB Receptors
Type of study:
Prognostic_studies
Limits:
Female
/
Humans
Language:
En
Journal:
J Clin Pathol
Year:
1993
Document type:
Article